T79604 |
SHR5428
|
|
98%
|
|
SHR5428 is an orally active, selective, noncovalent inhibitor of CDK7, displaying potent enzymatic inhibition (IC50 = 2.3 nM) and effectively suppressing cellula...
|
T79606 |
CAF-382
|
|
98%
|
|
CAF-382 (compound B1), an analog of SNS-032, functions as a CDKL5 and pan-CDK inhibitor, exhibiting modest inhibitory activity against GSK3α/β with an affinity g...
|
T79631 |
CDK9-IN-26
|
|
98%
|
|
CDK9-IN-26, also known as compound 1, is a potent inhibitor of Cyclin-Dependent Kinase 9 (CDK9) with an IC50 value of 0.18 μM.[1]
|
T79640 |
ZNL-05-044
|
|
98%
|
|
ZNL-05-044, a CDK11 inhibitor, exhibits IC50 values of 0.23 μM for CDK11A and 0.27 μM for CDK11B, as determined by NanoBRET assay. It induces G2/M cell cycle arr...
|
T79648 |
CDK2-IN-19
|
|
98%
|
|
CDK2-IN-19 (Compound 32) is a selective, orally active inhibitor of CDK2 (K i: 0.18 nM) that exhibits anticancer activity in mice with OVCAR3 tumors [1].
|
T79704 |
CDK9-IN-28
|
|
98%
|
|
PROTAC CDK9/CycT1 Degrader-1 (compounds 10), a potent CDK9 inhibitor, serves as a target protein ligand for PROTAC synthesis. Exhibiting substantial anti-prolife...
|
T79862 |
Tacaciclib
|
2768774-66-7
|
98%
|
|
Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].
|
T79863 |
Tibremciclib
|
2397678-18-9
|
98%
|
|
Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].
|
T79881 |
CDK7-IN-25
|
2009209-60-1
|
98%
|
|
CDK7-IN-25 (CY-16-1) is a potent CDK7 inhibitor with an IC50 value of less than 1nM, utilized in cancer research [1].
|
T79904 |
PROTAC CDK9/CycT1 Degrader-2
|
|
98%
|
|
PROTAC CDK9/CycT1 Degrader-2 inhibits CDK9 with an IC50 of 45 nM [1].
|
T82757 |
CDK9-IN-29
|
2737262-24-5
|
98%
|
|
CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM. It effectively hinders cell proliferati...
|
T82758 |
CDK9-Cyclin T1 PPI-IN-1
|
|
98%
|
|
CDK9-Cyclin T1 PPI-IN-1 (Compound B19) is a selective inhibitor of the CDK9-Cyclin T1 protein-protein interaction (PPI), suppressing cell proliferation in TNBC M...
|
T82759 |
CDK2-IN-20
|
|
98%
|
|
CDK2-IN-20 (compound 3b), a CDK2 inhibitor, exhibits cytotoxic effects on tumor cells with an IC50 ranging from 5.52-17.09 µM. It arrests the MCF-7 cell cycle at...
|
T10737 |
CDK4/6-IN-3
|
2366237-37-6
|
98%
|
|
CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.
|
T16038 |
Men 10376
|
135306-85-3
|
98%
|
|
Men 10376 is a selective antagonist of tachykinin NK-2 receptor. It has a Ki of 4.4 μM for rat small intestine NK-2 receptor.
|
TN4263 |
Isoangustone A
|
129280-34-8
|
98%
|
|
Isoangustone A has antitumor activity, it can induce G1 cycle arrest in DU145 human prostate and 4T1 murine mammary cancer cells, it inhibits cell proliferation ...
|
T11309 |
FMF-04-159-2
|
2364489-81-4
|
98%
|
|
FMF-04-159-2 inhibits CDK14 and CDK2 with IC50s of 39.6 nM and 256 nM in NanoBRET assay, respectively. FMF-04-159-2 is a covalent CDK14 inhibitor.
|
T10739 |
CDK8/19-IN-1
|
1818427-07-4
|
98%
|
|
CDK8/19-IN-1 is a selective and oral bioavailable CDK8/19 dual inhibitor (IC50s: 0.46 nM, 0.99 nM, and 270 nM for CDK8, CDK19, and CDK9).
|
T15730 |
Ribociclib hydrochloride
|
1211443-80-9
|
98%
|
|
Ribociclib hydrochloride is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively). It is over 1,000-fold less potent against the cyclin B/CDK1...
|
T13425 |
(1S,3R,5R)-PIM447 dihydrochloride
|
T13425
|
98%
|
|
(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).
|